In a block­buster fran­chise race, No­vo’s Trulic­i­ty ri­val scores more promis­ing late-stage di­a­betes da­ta

As No­vo Nordisk hus­tles up an oral ver­sion of its GLP-1 di­a­betes drug Ozem­pic for FDA re­view, the big Eli Lil­ly com­peti­tor has post­ed an­oth­er pos­i­tive late-stage piece of the da­ta puz­zle for its ri­val to Trulic­i­ty.

No­vo post­ed a pos­i­tive pro­file for its Phase II­Ib study com­bin­ing Ozem­pic (the in­jectable semaglu­tide) with an SGLT-2 drug, com­par­ing it with SGLT-2 plus a place­bo. The mag­ic num­ber in this field is an A1C num­ber of 7% or less. Start­ing with a mean base­line num­ber of 8%, the Ozem­pic com­bo cut AIC by 1.5% com­pared to 0.1% for a place­bo — which doesn’t say much for SGLT-2.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER